WE CLAIM:

1	1. A solid dosage form comprising:		
2	bupropion hydrochloride; and		
3	a stabilizer, wherein the stabilizer comprises glucono delta lactone or its		
4 · ·	corresponding open chain hydroxy acid derivative.		
1	2. The solid dosage form of claim 1, wherein the bupropion		
2	hydrochloride retains at least 80% of the bupropion hydrochloride potency after		
3	rage for three months at 40°C and 75% relative humidity.		
1	3. The solid dosage form of claim 1, wherein the stabilizer is glucono		
2	delta lactone.		
1	4. The solid dosage form of claim 1, wherein the stabilizer is a		
2	corresponding open chain hydroxy acid derivative of glucono delta lactone.		
1	5. The solid dosage form of claim 4, wherein the corresponding open		
2	chain hydroxy acid derivative of glucono delta lactone is gluconic acid.		
1	6. The solid dosage form of claim 1, wherein the concentration of		
2	glucono delta lactone or corresponding open chain hydroxy derivative comprises from		
3	about 5% to about 100% by weight of the bupropion hydrochloride.		
1	7. The solid dosage form of claim 1, wherein the concentration of		
2	glucono delta lactone or corresponding open chain hydroxy derivative comprises from		
3	about 5% to about 50% by weight of the bupropion hydrochloride.		
1	8. The solid dosage form of claim 1, wherein the amount of bupropion		
2	hydrochloride comprises between about 25 and about 500 mg w/w of the solid dosage		
3	form.		
1	9. The solid dosage form of claim 1, wherein the solid dosage form		
2	comprises one or more of a tablet, a capsule, and a granulate with or without an		
3	immediate release profile, a modified release profile, or an extended release profile.		
1	10. The solid dosage form of claim 9, wherein the solid dosage form		
2	comprises a tablet.		

WO 2004/045584 PCT/IB2003/005195

1	11. The solid dosage form of claim 10, wherein the tablet comprises a		
2	sustained release tablet.		
1	12. The solid dosage form of claim 9, wherein the solid dosage form		
2	comprises a capsule.		
1	13. The solid dosage form of claim 12, wherein the capsule comprises a		
2	sustained release capsule.		
1	14. The solid dosage form of claim 1, further comprising one or more		
2	pharmaceutically acceptable excipients comprising one or more of rate controlling		
3	polymers, diluents, binders, disintegrants, lubricants, glidants, and coloring agents.		
1	15. The solid dosage form of claim 14, wherein the release rate controlling		
2	polymers comprises one or more of cellulose derivatives, acrylates, a mixture of		
3	polyvinlyacetate and povidone, polyethylene oxides, starch and its derivatives, gums,		
4	alginates, carbohydrate based polymers, and polysaccharide.		
1	16. The solid dosage form of claim 14, wherein the cellulose derivative		
2	comprises one or more of ethyl cellulose, methylcellulose, hydroxymethylcellulose,		
3	hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, and		
4	sodium carboxymethylcellulose.		
1	17. The solid dosage form of claim 16, wherein the cellulose derivative		
2	comprises hydroxypropyl cellulose.		
1	18. The solid dosage form of claim 14, wherein the diluent comprises		
2	microcrystalline cellulose.		
1	19. The solid dosage form of claim 14, wherein the lubricant comprises		
2	stearic acid.		
1	20. A process for preparing a solid dosage form of bupropion		
2	hydrochloride, the process comprising;		
3	mixing bupropion hydrochloride and a stabilizer to form a blend, wherein the		
4	stabilizer comprises glucono delta lactone or its corresponding open chain hydroxy		
5	acid derivative; and		
6	forming the blend into a solid dosage form.		

WO 2004/045584 PCT/IB2003/005195

1	21.	The process of claim 20, wherein the solid dosage form retains at least		
2	80% of the b	80% of the bupropion hydrochloride potency after storage for three months at 40°C		
3	and 75% relative humidity.			
1	22.	The process of claim 20, wherein the stabilizer is glucono delta		
2	lactone.	. Wherein the stabilizer is glucono delta		
1	23.	The many C. 1.: 00 days		
2		The process of claim 20, wherein the stabilizer is a corresponding open		
	cham nydrox	y acid derivative of glucono delta lactone.		
1	24.	The process of claim 23, wherein the corresponding open chain		
2	hydroxy acid derivative of glucono delta lactone is gluconic acid.			
1	25.	The process of claim 20, wherein the concentration of glucono delta		
2	lactone or corresponding open chain hydroxy derivative comprises from between			
3	about 5% to about 100% by weight of bupropion hydrochloride.			
1	26.	The process of claim 25, wherein the concentration of glucono delta		
2		rresponding open chain hydroxy derivative comprises from between		
3		about 50% by weight of bupropion hydrochloride.		
1				
2	27.	The process of claim 20, wherein the amount of bupropion		
3		e comprises from between about 25 to about 500 mg w/w of the solid		
	dosage form.			
1	28.	The process of claim 20, wherein forming the blend into a solid dosage		
2		es forming a tablet, capsule or granulate with or without an immediate		
3	release profile	e, a modified release profile, or an extended release profile.		
1	29.	The process of claim 28, wherein the solid dosage form comprises a		
2	tablet.	,		
1	30.	The process of claim 29, wherein the tablet comprises a sustained		
2	release tablet.	25, wherein the tablet comprises a sustained		
ı				
•	31.	The process of claim 28, wherein the solid dosage form comprises a		
-	capsule.			
!	32.	The process of claim 31, wherein the capsule comprises a sustained		
2	release capsul	e		

WO 2004/045584 PCT/IB2003/005195

1	33. The process of claim 20, wherein the mixing comprises wet		
2	granulation.		
1 2	34. The process of claim 20, wherein the mixing comprises dry granulation.		
1 2	35. The process of claim 20, wherein the mixing comprises direct compression.		
1	36. The process of claim 20, wherein the solid dosage form further		
2	comprises one or more pharmaceutically acceptable excipients selected from rate		
3	controlling polymers, diluents, binders, disintegrants, lubricants, glidants and coloring		
4	agents.		
1	37. The process of claim 36, wherein the release rate controlling polymer		
2	comprises one or more of cellulose derivatives, acrylates, a mixture of		
3	polyvinlyacetate and povidone, polyethylene oxides, starch and their derivatives,		
4	gums, alginates, carbohydrate based polymers, and polysaccharide.		
1	38. The process of claim 37, wherein the cellulose derivative comprises		
2	one or more of ethyl cellulose, methylcellulose, hydroxymethylcellulose,		
3	hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, and		
4	sodium carboxymethylcellulose.		
1	39. The process of claim 38, wherein the cellulose derivative comprises		
2	hydroxypropyl cellulose.		
1	40. The process of claim 36, wherein the diluent comprises		
2	microcrystalline cellulose.		
1	41. The process of claim 36, wherein the lubricant comprises stearic acid.		
1	42. A method of treating either or both of depression and nicotine		
2	addiction in a human, the method comprising orally administering to a human in need		
3	thereof a solid dosage form comprising bupropion hydrochloride and a stabilizer,		
4	wherein the stabilizer comprises glucono delta lactone or its corresponding open chain		
5	hydroxy acid derivative.		
1	43. The method of claim 42, wherein the bupropion hydrochloride retains		
2	at least 80% of the bupropion hydrochloride potency after storage for three months at		
2	1000 1550 at 1		

40°C and 75% relative humidity.

3

WO 2004/045584 PCT/IB2003/005195

1 2	44. lactone.	The method of claim 42, wherein the stabilizer is glucono delta
1 2	45. chain hydrox	The method of claim 42, wherein the stabilizer is a corresponding open y acid derivative of glucono delta lactone.
1 2	46. hydroxy acid	The method of claim 45, wherein the corresponding open chain derivative of glucono delta lactone is gluconic acid.
1 2 3	47. The method of claim 42, wherein the concentration of glucono delta lactone or corresponding open chain hydroxy derivative comprises from about 5% to about 100% by weight of the bupropion hydrochloride.	
1 2 3		The method of claim 42, wherein the concentration of glucono delta responding open chain hydroxy derivative comprises from about 5% to weight of the bupropion hydrochloride.
1 2 3	49. hydrochloride form.	The method of claim 42, wherein the amount of bupropion comprises between about 25 and about 500 mg w/w of the solid dosage
1	50.	The method of claim 42, wherein the solid dosage form comprises one

or more of a tablet, a capsule, and a granulate with or without an immediate release

profile, a modified release profile, or an extended release profile.

2

3